Crossmark

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase

Crossref DOI link: https://doi.org/10.1038/s41418-021-00788-x

Published Online: 2021-05-13

Published Print: 2021-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fiorillo, Marco

Scatena, Cristian

Naccarato, Antonio Giuseppe

Sotgia, Federica

Lisanti, Michael P. https://orcid.org/0000-0003-2034-1382
Funding

Funding for this research was provided by:

Lunella Biotech, Inc.
License Information

Text and Data Mining valid from 2021-05-13

Version of Record valid from 2021-05-13
More Information

Article History

Received: 23 October 2020

Revised: 9 April 2021

Accepted: 15 April 2021

First Online: 13 May 2021

Compliance with ethical standards

:

: A provisional patent application (WO/2021/048830) covering this technology has been filed by Lunella Biotech, Inc. MPL and FS hold a minority interest in Lunella Biotech, Inc.

Document is current

Any future updates will be listed below